Q2 2023 · 13F-HR
Kynam Capital Management, LPholdings as filed
Filed 2023-08-14 · accession 0001085146-23-003327
$727.1M
Reported value
26
Positions
2023-06-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 632307104 | NTRA | NATERA INC | $141.1M | 19.4% | 2,900,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $88.2M | 12.1% | 2,600,000 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE | $71.8M | 9.88% | 184,300 | PUT | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $68.3M | 9.39% | 3,262,004 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $64.9M | 8.93% | 1,300,000 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $49.5M | 6.81% | 4,890,706 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $48.1M | 6.62% | 3,000,000 | Common | SOLE |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $26.9M | 3.70% | 975,298 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $22.3M | 3.07% | 1,454,730 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $20.1M | 2.76% | 2,848,197 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $19.1M | 2.63% | 1,617,391 | Common | SOLE |
| 12233L107 | BNR | BURNING ROCK BIOTECH LTD | $18.3M | 2.52% | 8,500,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $16.9M | 2.32% | 709,498 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $14.3M | 1.96% | 3,924,602 | Common | SOLE |
| 023111206 | — | AMARIN CORP PLC | $14.3M | 1.96% | 12,000,000 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $12.9M | 1.77% | 1,642,244 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $11.8M | 1.62% | 1,304,332 | Common | SOLE |
| 869367102 | — | SUTRO BIOPHARMA INC | $7.0M | 0.96% | 1,500,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $4.5M | 0.62% | 729,077 | Common | SOLE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $1.7M | 0.23% | 473,070 | Common | SOLE |
| 31572Q808 | FGENEUR | FIBROGEN INC | $1.6M | 0.22% | 586,500 | CALL | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $1.5M | 0.21% | 92,602 | Common | SOLE |
| 69366J200 | PTCT | PTC THERAPEUTICS INC | $1.2M | 0.16% | 28,500 | CALL | SOLE |
| 207523101 | — | CONNECT BIOPHARMA HLDGS LTD | $602,640 | 0.08% | 535,005 | Common | SOLE |
| 64049K104 | — | NEOLEUKIN THERAPEUTICS INC | $99,572 | 0.01% | 119,966 | Common | SOLE |
| 14888D208 | — | CATALYST BIOSCIENCES INC | $31,604 | 0.00% | 89,886 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.